Tumor escape mechanisms in leukemia are not well defined. To dissect immunological mechanisms responsible for immune tolerance toward leukemia, we established a murine model system allowing clonotypic analysis of leukemia-specific CD4 T cells recognizing ovalbumin (OVA). Upon i.v. injection of genetically engineered leukemia cells, dendritic cells (DCs) engulfed, processed and presented OVA to OVA-specific CD4 T cells. Consequently, leukemia-specific T cells were primed in vivo as shown by expression of activation markers and proliferative responses. However, in spite of detectable CD4 T cell responses in vitro and in vivo, no effective anti-leukemia immunity was established. In contrast, adoptively transferred DO11.10 T cells that were primed ex vivo mediated effective antitumor immunity. Furthermore, ex vivo primed DO11.10 T cells showed high expression of Th1 cytokines (interferon-c, tumor necrosis factor-a and interleukin-2) whereas in vivo primed OVA-specific CD4 T cells showed incomplete differentiation (proliferation without cytokine production). We conclude that activated T cells lacking effector function develop through incomplete differentiation in leukemia-bearing mice. Thus, priming conditions of leukemia-specific CD4 T cells critically determines the balance between immunity or tolerance toward leukemia.
Introduction
The mechanisms governing the delicate balance between effective antitumor immunity and tumor immune escape are poorly understood. The study of genetically defined mouse tumor models has provided important insights into surveillance processes keeping tumor growth in check. For example, mice deficient for interferon-g (IFN-g), [1] [2] [3] IFN-gR, 4 ,5 perforin, 6, 7 natural killer cells, 8, 9 ab T cells, 5, 10 and gd T cells 11, 12 are more susceptible to develop spontaneous or carcinogen-induced tumors. Furthermore, lack of antigen presentation secondary to deficiencies of MHC molecules, 13 loss of antigenic epitopes, 14 decreased accessibility of tumors due to physical barriers, 15 immunological ignorance 16 and effects of suppressor T cells 17 are some of the mechanisms proposed to prevent effective antitumor immunity. More recently, it has become evident that defects in dendritic cells (DCs) play a critical role in nonresponsiveness to tumors. Abnormal differentiation of myeloid cells, potentially caused by immunomodulatory cytokines, may result in differentiation of tolerogenic DCs, thus subverting effective T-cell responses against malignant cells.
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Several studies have pointed out a critical role for CD4 T cells in antitumor immunity. [19] [20] [21] [22] Although the role for CD4 T cells as helpers for efficient CD8 effector T-cell function is well established, it has not been known whether antigen presenting cells (APCs) can efficiently activate tumor-specific CD4 T cells during a primary immune response. Corthay et al. 23 documented for the first time that tumor-specific CD4 T cells activated macrophages in close proximity to tumor cells resulting in complete inhibition of tumor growth. However, whether inefficient or subverted CD4 T-cell priming is a critical and significant mechanism accounting for immunoevasion of leukemia remains unknown. In contrast to solid tumor models, leukemia represents by definition a systemic disease. Therefore immunological mechanisms controlling tolerance and immunity may be distinct from mechanisms of immune response against solid tumors.
We hypothesized that decreased activation of tumor-specific CD4 T cells might contribute to functional tolerance against acute lymphoblastic leukemia. To address this question, we set up a transgenic model system that allows clonotypic analysis of CD4 T cells reacting against ovalbumin (OVA)-expressing BCR-ABL þ acute lymphoblastic leukemia cells.
Materials and methods

Mice
Female BALB/c mice (6 to 8-weeks old) were purchased from Charles Rivers (Sulzfeld, Germany), mice transgenic for OVA 323-339 -specific DO11.10 a/b-TCR 24 were kindly provided by Dr T Kamradt, Berlin. All mice were maintained under specific pathogen-free conditions at the central animal facility of the Hannover Medical School. Animal care and experiments were done in accordance with institutional and national guidelines.
Cell lines
The BALB/c BCR-ABL þ pre-B-cell leukemia cell line, BM185 cell line was established by transducing bone marrow of BALB/c with a retroviral vector encoding the 185-kDa BCR-ABL protein. 25 The virus packaging cell line 293GPG was maintained in 10% fetal calf serum (FCS) Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 1% penicillin-streptomycin, 1 mg/ml tetracycline, 2 mg/ml puromycin and 0.3 mg/ml neomycin (GIBCO, Karlsruhe, Germany).
Construction of retroviral vectors and generation of BM185-derivative cell lines
The cDNA encoding OVA was cloned into the retroviral transfer vector pMMP, 26 respecting the original env start codon. The bicistronic vectors pMMP-OVA-IRES-GFP (green fluorescent protein) and pMMP-OVA-IRES-PURO (puromycin) were created by insertion of the IRES-GFP or IRES-PURO sequence from the plasmid MSCV2.2-IRES-GFP 27 or pBabe-IRES-PURO, respectively (Figure 1a) . VSV-G-pseudotyped retroviruses were generated by transient transfection of the virus packaging cell line 293GPG as previously described. 26 The viral titers were determined by transducing NIH3T3 or A549 cells. To generate BM185-derivative cell lines, BM185 cells were mixed with retroviral supernatants in the presence of 8 mg/ml polybrene (Sigma, Munich, Germany), subjected to spinoculation for 2 h at 1000 g at 32 1C and then incubated for 12 h at 37 1C. The transduction efficiency was determined by fluorescence-activated cell sorting (FACS).
The BM185 and the derivative cell lines, BM185-OVA-GFP,  BM185-GFP, BM185-OVA-GFP-PURO, BM185-GFP-PURO,  BM185-CD40L-CD80-GM/CSF-OVA-GFP-PURO, BM185-CD40L-CD80 -GM/CSF-GFP-PURO were grown in 10% FCS RPMI 1640 supplemented with 2 mM L-glutamine, 1% PenicillinStreptomycin (GIBCO). The transduced cells were either sorted by MoFlow with a purity of 498% or selected with 2.5 mg/ml puromycin (GIBCO).
Flow cytometry
Single cell suspensions were analyzed by flow cytometry using FACS Calibur or FACS Canto and CELLQuest software, FACS Diva software (BD Biosciences) or Flow Jo software (Tree Star).
In some experiments, cell sorting was performed using a MoFlow cell sorter (DAKO, Hamburg, Germany). Cells were phenotyped by their expression of surface markers using direct immunofluorescence staining techniques. The cells were pretreated with CD16/32 for blocking Fc receptors, incubated for 20 min on ice with 100 ml of FACS buffer (phosphate-buffered saline (PBS) þ 2% FCS) containing 0.5 mg of various mAbs conjugated to fluorescein isothiocyanate, phycoerythrin (PE), biotin, PerCP or APC (BD Pharmingen, San Jose, CA, USA). For biotinylated mAbs, streptavidin-allophycocyanin or streptavidin-PerCP was used as a second-step reagent. The following monoclonal antibodies (all from BD Pharmingen except noted otherwise) were used: CD3e, CD4, CD8a, CD11b, CD11c, CD25, CD27, CD40, CD44, CD62L, CD69, CD80, CD86, CD127, CD134, CD278, CCR7 (Ebioscience, San Diego, CA, USA), B220, H2-K d I-A d GR-1 and Ly6C. To detect OVA-specific CD4 T cells, cells were stained with the KJ1-26 monoclonal antibody (Caltag, Hamburg, Germany) that binds specifically to the TCR heterodimer recognizing OVA 323-339 bound to I-A d class II MHC molecules. 28 In all experiments, cells were also stained with corresponding isotype-matched monoclonal antibodies. All fluorescence-intensity plots are shown in log scales. For the leukemia cell uptake experiments the BM185 cell were stained with the lipophilic dye PKH26 (Sigma). For DC enrichment, OptiPrep gradient was used according to the manufacture's protocol (Axis-Shield, Oslo, Norway).
Intracellular cytokine expression
Single cell suspensions were stimulated with phorbol 13-myristate 12-acetate (10 À7 M) and ionomycin (1 mg/ml) in the presence of brefeldin A (10 mg/ml) for 4-6 h (Sigma). Cells were pretreated with anti-CD16/32 monoclonal antibodies, followed by staining using PerCP-conjugated-KJ1-26 (Caltag), and APCconjugated anti-CD4 (BD Pharmingen). For cytokine detection, a commercially available kit (FIX & PERM, Caltag) was used. Briefly, cells were fixed in Medium A, followed by intracellular staining in permeabilization buffer (Medium B) and PE-conjugated IFN-g, interleukin-2 (IL-2), IL-4, IL-10 or tumor necrosis factor-a (TNF-a; BD Pharmingen). Cells were washed, resuspended in 1% FCS/PBS solution and analyzed by flow cytometry.
Animal experiments
Leukemia cells in exponential growth phases were harvested, washed in PBS, and then injected in a volume of 0.5 ml into the tail vein. The mice were monitored daily and moribund mice were killed according to the animal protection guidelines. In experiments requiring adoptive transfer of DO11.10 T cells, lymph nodes and spleens were isolated from DO11.10 mice. The percentage of CD4 þ KJ1-26 þ T cells was determined before transfer by FACS, 2 Â 10 6 CD4 þ KJ1-26 þ T cells were transferred on day 1-2 after leukemia challenge. For in vivo immunization against OVA, mice were injected i.v. with 400 mg OVA (Sigma) dissolved in PBS.
To prime DO11.10 T cells ex vivo, lymph node and spleen cells from DO11.10 (2 Â 10 6 per ml) mice were cultured in modified RPMI 1640 culture medium containing 10% FCS, glutamine, antibiotics and 1 mg/ml OVA (Sigma). After culture for 4-6 days in a humidified 5% CO 2 in-air incubator, cells were washed and purified by MoFlow or CD4 isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
5,6-carboxy-succinimidyl-fluoresceine-ester labeling of T cells
5,6-Carboxy-succinimidyl-fluoresceine-ester (CFSE) labeling was performed as previously described. 29 Briefly, DO11.10 splenocytes were resuspended in PBS at 10 7 cells per ml and were labeled with 5 mM of CFSE (Molecular Probes, Eugene, OR, USA) at 37 1C for 10 min. The cells were quenched with equal volume of FCS for 1 min and washed three times with PBS before adoptive transfer.
Thymidine incorporation assay DO11.10 T cells were incubated at different antigen-presenting cell (APC)/T-cell ratios in U-bottomed, 96-well plate. T-cell proliferation was assessed after 3 days by 3 H thymidine (1 mCi per well) uptake in a 16-h pulse. In some experiments; MACSsorted DCs from spleens of leukemia-bearing mice were used as stimulators.
Statistical analysis
The Kaplan-Meier plots for tumor survival were assessed for significance with the log-rank test. For other data, the significance of differences between the experimental groups was analyzed using the Student's t-test. For all analyses, the level of significance was set at a probability of 0.05 to be considered significant.
Results
Generation and characterization of murine BCR-ABL þ leukemia cells expressing marker genes
To establish a murine model system allowing in vivo tracking and analysis of leukemia-specific clonotypic CD4 T-cell responses, we genetically modified BM185 cells, a previously generated BCR-ABL transgenic-B lymphoblastic leukemia cell line. 25, 30 BM185-derivative cell lines were established using retroviral gene transfer and subsequent FACS sorting or puromycin selection of transduced cells. Thus, BM185-OVA-GFP cells expressing intracellular OVA and BM185-GFP cells were made. Previously it has been shown that mice receiving BM185 cell lines expressing the immunomodulatory molecules granulocyte monocyte colony stimulating factor (GM-CSF), CD80 and CD40L had enhanced survival. 31 We thus generated highly immunogenic cell lines as positive controls (BM185-40L-80-GM-OVA-GFP-PURO and BM185-40L-80-GM-GFP-PURO). All derivative leukemia cells expressed B220, CD19, CD5 and MHC class I, and were negative with respect to expression of CD3, CD40, CD80, CD86 and MHC class II ( Figure 1b) ; this phenotype was not altered in vivo (data not shown). Transgene expression in genetically engineered leukemia cells was confirmed by FACS analysis (Figure 1c ) and enzyme-linked immunosorbent assay (data not shown). As BM185-derivative cells do not express MHC class II, OVA-specific DO11.10 T-cell responses critically depend on cross-presentation by host antigen presenting cells. This was experimentally confirmed by incubating DO11.10 T cells with BM185-OVA-GFP and BM185-GFP cells, respectively, or pulsing BM185-GFP cells with OVA 323À339 peptide. Neither BM185-GFP nor BM185-OVA-GFP induced proliferation of DO11.10 T cells (data not shown).
Next, we tested the in vivo leukemogenicity of the cell lines. We chose a lethal tumor dose of 2 Â 10 6 leukemia cells enabling us to analyze the tumor-host interaction at early time points. Upon i.v. injection, all derivative cells with the exception of the immunogenic cell lines expressing CD40L, CD80 and GM-CSF proliferated rapidly, leukemia blasts were detected in blood and led to death within 10-15 days after injection (Figure 1d ). To further characterize in vivo growth characteristics of the BM185-derived cell lines, we enumerated the leukemia cells in various lymphoid compartments at 3, 6 and 9 days after injection. Proportionally, more leukemia cells could be detected in bone marrow compared to spleen and lymph nodes. Interestingly, in all lymphoid compartments analyzed, a higher proportion of BM185-GFP cells (compared to BM185-OVA-GFP cells) were detected as shown in Figure 1e , suggesting that the cell lines do differ in their level of immunogenicity. As expected, the highly immunogenic cell line BM185-40L-80-GM-OVA-GFP-PURO could not be detected in vivo at any time point. Thus, we had established a transgenic OVA-expressing leukemia cell system that should allow the in vivo detection and functional analysis of leukemia-specific CD4 T cells.
Functional analysis of splenic dendritic cells in leukemic mice
Induction of specific antitumor immune responses requires a complex series of events involving efficient uptake of tumor cells by DCs, presentation of tumor antigens and priming of specific 
CD11c
þ DCs but not in CD8a À CD11c þ cells, indicating that BM185 cells were effectively ingested by 'lymphoid' DCs. To screen for major immunophenotypic alterations, we analyzed the cell-surface expression of MHC class I, MHC class II, CD40, CD80 and CD86 on CD11c þ splenic DCs. As shown in Figure 2b , DCs isolated from leukemia-bearing animals showed decreased cell-surface expression levels of MHC class II, whereas expression of CD40, CD80 and CD86 was comparable to DCs isolated from control animals. This slight downregulation of the MHC class II had no effect on the stimulatory capacity of the DCs ex vivo (Figure 2c) . Next, we asked the question whether DCs from leukemia-bearing mice could process and present leukemia-specific antigens, using OVA as a surrogate leukemia-specific antigen. Groups of three mice were i.v. injected with 2 Â 10 6 BM185-OVA-GFP and BM185-GFP cells, respectively. Nine days later, splenic CD11c þ DCs were purified by immunomagnetic sorting and used as stimulator cells in coculture with naive DO11.10 T cells. As shown in Figure 2d , DCs isolated from mice injected with BM185-OVA-GFP stimulated a proliferative T-cell response, whereas control DCs were unable to induce specific T-cell proliferation, suggesting that ingested tumor cells were processed and that tumor antigens were cross-presented in vivo.
Analysis of leukemia-specific CD4 T-cell response
Having established that DCs in principle can process and present tumor-specific antigens to CD4 T cells, we were further interested in leukemia-specific CD4 T-cell responses in vivo. We adoptively transferred 2 Â 10 6 CFSE-labeled DO11.10 T cells into leukemia-bearing mice. Mice injected with BM185-GFP cells served as negative controls and mice injected with OVA served as positive controls. All animals were killed on days 3, 6 and 9 to assess the number and activation status of DO11.10 T cells (Figure 3a) . As shown in Figure 3b , a strong proliferative response of DO11.10 T cells could be documented on days 6 and 9 in OVA-injected mice both in lymph nodes and in spleens. In contrast, BM185-OVA-GFP induced a weaker proliferative response predominantly seen in spleen and only marginally detectable in lymph nodes. Such increase in proliferative activity resulted in increased cell numbers (Figure 3c ) and upregulation of the activation marker CD44 (Figure 3d ). We were also interested to see whether this leukemia-specific T-cell activation and proliferation would induce regression of BM185-OVA-GFP leukemia upon adoptive transfer of OVA-specific CD4 T cells. To address this question, one day after injection of 2 Â 10 6 BM185-GFP or BM185-OVA-GFP leukemia cells, 2 Â 10 6 DO11.10 T cells were administered and the survival was monitored. In spite of the documented OVA-specific T-cell proliferation and activation, all mice succumbed to progressive leukemia (Figure 3e ), suggesting that DO.11.10 T cells are unable to induce sustained remission of leukemia.
Immunogenic leukemia cell line induces robust CD4 T-cell proliferation and Th1 polarization
In spite of measurable CD4 anti-leukemia T-cell responses, adoptive transfer of naive DO11.10 T cells did not induce protective antitumor immune responses. In contrast, the immunogenic BM185-derived leukemia cell line expressing CD40L, CD80 and GM-CSF induced very strong, sustained anti-leukemia immunity 31 ( Figure 1e ). To assess the effects of the immunogenic cell line on CD4 T cells response, we further engineered BM185-40L-80-GM-GFP to express OVA by means of retroviral transduction and selection for puromycin resistance. In subsequent experiments, this cell line was used as a positive control inducing effective anti-leukemia response. Upon i.v. injection, BM185-40L-80-GM-OVA-GFP-PURO leukemia cells induced a rapid OVA-specific T-cell response which was stronger than the T-cell response of BM185 parent cell line (Figures 4a and b) , suggesting that more efficient CD4 T-cell priming leads to complete leukemia rejection in vivo. We therefore hypothesized that priming of DO11.10 T cells by BM185-OVA-GFP in vivo results in either insufficient or subverted CD4 T-cell responses associated with noneffective anti-leukemia immunity. To address this question, we measured the cytokine profile of DO11.10 T cells upon in vivo priming by intracytoplasmic staining and FACS analysis. In these experiments, we included DO11.10 T cells primed by the highly immunogenic cell line BM185-40L-80-GM-OVA-GFP-PURO as a positive control. In spite of considerable OVA-specific proliferative activity and upregulation of activation markers such as CD25, CD69 and CD44, DO11.10 T cells isolated from BM185-OVA-GFP bearing mice did not express increased levels of IL-2 or IFN-g (Figure 4c ). In fact, the expression levels of IL-2 and IFN-g did not differ between the mice injected with BM185-OVA-GFP-PURO and the negative controls. Furthermore, no measurable expression of Th2 cytokines such as IL-4 and IL-10 could be demonstrated (data not shown). In contrast, DO11.10 T cells obtained from mice injected with BM185-40L-80-GM-OVA-GFP-PURO cells revealed high levels of IL-2 and IFN-g production, indicating that a robust Th1 differentiation was induced by the immunogenic leukemia cell line (Figure 4d ). These findings suggest that deficient anti-leukemia immunity in BM185-OVA-GFP mice can, at least partially, be explained by insufficient Th1 priming.
Ex vivo priming of leukemia-specific CD4 T cells results in potent anti-leukemia immunity
To further substantiate the concept of insufficient in vivo priming and subsequent deficiency of Th1 cytokine expression in primed DO11.10 T cells, we reasoned that adoptively transferred DO11.10 T cells that had undergone ex vivo priming may display a higher degree of antitumor immunity. We isolated DO11.10 T cells and incubated them in the presence of OVA and syngeneic splenocytes. Four days later, their activation status was screened by FACS. As shown in Figure 5a (and Supplementary Figure 1) , in vitro primed DO11.10 T cells showed increased expression of CD25, CD44 and CD69 and 6 BM185-OVA-GFP or as a negative control either 2 Â 10 6 BM185-GFP or PBS. Nine days after leukemia injection, splenic DCs were MACS isolated and varying numbers of splenic DCs were cocultered with DO11.10 lymph node cells. T-cell proliferation was measured in triplicate by incorporation of 3H-thymidine.
downregulation of CD62L, a phenotype consistent with effector T cells. Surprisingly, ex vivo primed DO11.10 T cells maintained IL-7Ra and CCR7 expression. Furthermore, the majority of DO11.10 T cells showed a Th1 cytokine pattern as shown with expression of IFN-g, TNFa and IL-2 ( Figure 5b ). We adoptively transferred these ex vivo primed DO11.10 T cells into mice that received either BM185-OVA-GFP or BM185-GFP leukemia and followed their survival over time. As shown in Figure 5c and d, ex vivo primed DO11.10 T cells significantly prolonged the mean survival to 490 days in mice injected with BM185-OVA-GFP cells (Figure 5c ). In contrast ex vivo primed DO11.10 T cells had no protective effects on mice that had been previously injected with BM185-GFP cells (Figure 5d ). Thus, ex vivo primed leukemia-specific CD4 T cells can induce a significant improvement of long-term survival, reflecting sustained anti-leukemia immunity.
Discussion
We present three key findings indicating that insufficient priming of IFN-g-expressing CD4 T cells is responsible for immune evasion of acute lymphoblastic leukemia cells.
(1) In leukemia-bearing mice, specific CD4 T cells are primed in vivo and generate a measurable proliferative response but do not differentiate fully to effector helper cells in vivo. Thus, they fail to protect mice from progressive leukemia. All findings taken together, our experiments point to a critical role of Th1 CD4 T cells in providing immunological surveillance against leukemia. Thus, here we identify a distinct mechanism of immune escape in a murine model of ALL. 
þ cells in spleen at day 9 after leukemia injection (n ¼ 3).
Previous studies in various solid tumor models suggested that CD4 T cell help is needed for efficient CD8-mediated tumor destruction. 32 Various investigators addressed this issue by experiments using adoptive transfer [33] [34] [35] or depletion of CD4 T cells [36] [37] [38] to substantiate the role for CD4 mediated antitumor immunity. Mechanistically, the role of CD4 T cells is still not completely understood. CD4 T cells are known to be required for priming and maintaining CD8 þ antitumor cytotoxic T cells. 21, 39 CD4 T cells also function to maintain the numbers and cytotoxic capacity of CD8 T cells and promote the infiltration of CD8 T cells into tumors. 40, 41 In some models, CD4 T cells themselves are able to reject tumors in the absence of CD8 T cells. 22, 42 More recently, CD4 T cells have been shown to convert directly into cytolytic CD8 cells 43 or to acquire components of the DC antigen-presenting machinery and thus stimulate antitumor CTL responses. 44 Analysis of the participation of distinct T-cell populations in elimination of Friend murine leukemia virusinduced tumor FBL-3 showed that tumor-specific CD4 T cells in combination with cyclophosphamide can exert their effect independently of CD8 T cells. 33 Thus, our investigations extend previously published concepts and point to a specific priming deficiency of anti-leukemia CD4 T cells affecting proper tumor surveillance, whereas the role of CD8 T cells in CD4 T cell-based adoptive immunotherapy remains to be investigated.
Although it is currently not known whether immunity to solid tumors differs from immunity to hematologic malignancies, we assume that the widespread anatomic localization of hematologic malignancies has implications for immunological mechanisms determining antitumor immunity. Our model of BCR-ABL transgenic ALL cells, previously used to develop novel immunotherapeutic approaches, 25, 30 offers the advantage of analyzing the CD4 T-cell response against a surrogate tumor antigen. A limitation of our system is the fact that OVA is a xenogeneic protein. Nevertheless, even though BM185-derived cells expressing GFP and/or OVA show a certain degree of immunogenicity in vivo, as shown by our data and by others, 45 these genetically engineered leukemia cells are not rejected and uniformly lead to death secondary to overwhelming leukemia. Therefore, BM185-derivative cells can be used to dissect immunological mechanisms of immune evasion in systemic malignancies.
We originally hypothesized that a focus on DC may point to a conclusive mechanism explaining decreased priming of antileukemic CD4 T-cell responses. However, our analysis of DC yielded equivocal results. We documented that DCs in leukemia-bearing mice are in principle capable of ingesting, processing and presenting tumor antigens to CD4 T cells. Consistently, their expression levels of MHC class II appeared reduced compared to control DCs, a finding reminiscent of data published by other groups. 18 In principle, reduced expression of MHC class II on DC might account for decreased stimulation of CD4 T cells.
Although our data are not supportive of this hypothesis, it remains to be shown weather downregulation of MHC II on DCs may have a role in the decreased CD4 T-cell priming in leukemia.
Our studies support a critical role of Th1 differentiation in orchestrating effective anti-leukemia immunity. Interestingly, careful analysis of IFN-g knockout mice 1 has recently revitalized the concept of immunosurveillance. 46 IFN-g is produced by many cell types and it is currently not known which of these cells are important to mediate effective antitumor immunity. Gao et al. 12 have shown that IFN-g producing gd T cells are important mediators of antitumor immunity. Recently, it has been shown that CD4 T-cell-mediated antitumor immunity involves IFN-g-dependent inhibition of tumor-induced angiogenesis. 47 We here provide evidence that IFN-producing CD4 T cells represent critical players in anti-leukemia immunity, supporting previously published evidences. 22, 23, 33, 47 In a solid tumor model, Mumberg et al. 22 have previously shown that antitumor effects of adoptively transferred CD4 T cells depend on IFN-g. In contrast to our model, these authors used a fibrosarcoma system subcutaneously injected into SCID mice that could be rejected independently of CD8 T cells. These authors concluded that host cells and not tumor cells seem to be the target of IFN-g. This is in line with other observations in localized tumor models describing activation and recruitment of macrophages and eosinophils. 21, 23 We could not provide any evidence that myeloid cell activation plays a critical role in the BM185-based generalized leukemia system. In human patients, a role for IFN-g in maintaining immunosurveillance is much less clear. Our own observations in children presenting with B-lineage ALL indicate that polymorphic IFN-g alleles are associated with age at clinical presentation and clinical risk groups. 48 Subversion of immunological tolerance toward leukemia might open novel therapeutic avenues to achieve successful anti-leukemia immunity. Strengthening the priming of antileukemia CD4 responses, for example, by forced expression of the tumor-necrosis factor LIGHT 49 or by optimized technologies allowing in vivo manipulation of DCs, 50 may eventually translate into clinically effective immunotherapeutic strategies to treat patients with leukemia.
